2024
Comparison of outcomes for Hispanic and non‐Hispanic patients with advanced renal cell carcinoma in the International Metastatic Renal Cell Carcinoma Database
Guram K, Huang J, Mouchati C, Abdallah N, Jani C, Navani V, Xie W, Zarif T, Adib E, Gebrael G, Agarwal N, Li H, Labaki C, Labban M, Morales J, Choueiri T, Heng D, Mittal A, Hansen A, Rose B, McKay R. Comparison of outcomes for Hispanic and non‐Hispanic patients with advanced renal cell carcinoma in the International Metastatic Renal Cell Carcinoma Database. Cancer 2024, 130: 2003-2013. PMID: 38297953, DOI: 10.1002/cncr.35216.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaOverall survivalNHW patientsStatistically significant differenceSystemic therapyCell carcinomaHazard ratioAdvanced renal cell carcinomaMetastatic renal cell carcinomaCancer CenterFirst-line treatment failureMultivariate Cox regression analysisIMDC risk groupsKaplan-Meier methodSignificant differenceCox regression analysisCox regression hazard ratiosTertiary cancer centerAuthors investigated outcomesNon-Hispanic patientsMedian OSComparison of outcomesMetastatic sitesBone metastasesTreatment failureBaseline bone pain as a prognostic marker for survival for men with metastatic hormone-sensitive prostate cancer (mHSPC): Patient-level analysis of SWOG 1216 trial.
Gebrael G, Jo Y, Swami U, Plets M, Hage Chehade C, Narang A, Gupta S, Myint Z, Sayegh N, Tangen C, Hussain M, Dorff T, Lara P, Lerner S, Thompson I, Agarwal N. Baseline bone pain as a prognostic marker for survival for men with metastatic hormone-sensitive prostate cancer (mHSPC): Patient-level analysis of SWOG 1216 trial. Journal Of Clinical Oncology 2024, 42: 188-188. DOI: 10.1200/jco.2024.42.4_suppl.188.Peer-Reviewed Original ResearchMetastatic hormone-sensitive prostate cancerProgression-free survivalAndrogen deprivation therapyBone painOverall survivalGleason scoreProstate cancerPrognostic markerAssociated with decreased PFSDisease burdenMedian progression-free survivalHormone-sensitive prostate cancerCastration-resistant prostate cancerCox proportional hazards modelsConfidence intervalsPatient-level analysisProportional hazards modelDeprivation therapyHigher disease burdenBone metastasesPain statusSurvival outcomesPatient-level dataTreatment intensificationPrognostic variables
2023
Associations amongst genes, molecules, cells, and organs in breast cancer metastasis
Nathanson S, Dieterich L, Zhang X, Chitale D, Pusztai L, Reynaud E, Wu Y, Ríos-Hoyo A. Associations amongst genes, molecules, cells, and organs in breast cancer metastasis. Clinical & Experimental Metastasis 2023, 41: 417-437. PMID: 37688650, DOI: 10.1007/s10585-023-10230-w.Peer-Reviewed Original ResearchBreast cancer metastasisBreast cancerCancer metastasisOutcomes of patientsAnti-tumor immunityHope of cureAggressive therapyMultiple metastasesAggressive treatmentBone metastasesLymph nodesSystemic metastasesMorphologic subtypesClinical oncologistsMetastasisInternal visceraAssists cliniciansLymphatic endothelial cellsPatientsEndothelial cellsHealth SymposiumBasic scientistsMolecular expressionCancerMolecular aspects
2022
Regulation of bone homeostasis by MERTK and TYRO3
Engelmann J, Zarrer J, Gensch V, Riecken K, Berenbrok N, Luu T, Beitzen-Heineke A, Vargas-Delgado M, Pantel K, Bokemeyer C, Bhamidipati S, Darwish I, Masuda E, Burstyn-Cohen T, Alberto E, Ghosh S, Rothlin C, Hesse E, Taipaleenmäki H, Ben-Batalla I, Loges S. Regulation of bone homeostasis by MERTK and TYRO3. Nature Communications 2022, 13: 7689. PMID: 36509738, PMCID: PMC9744875, DOI: 10.1038/s41467-022-33938-x.Peer-Reviewed Original ResearchConceptsCancer-induced bone lossBone homeostasisBone lossBone-resorbing osteoclastsBone metastasesProlong survivalOsteoanabolic therapyMultiple myelomaLung cancerBone-forming osteoblastsBone massHealthy micePreclinical modelsOsteoblast numberMerTKTyro3Bone formationMicePotent regulatorCell type-specific functionsFine equilibriumBlockadeCancerHomeostasisOsteoblast differentiationClinical predictors of longer survival in patients with BRAFV600-mutated metastatic melanoma receiving immunotherapy prior to BRAF/MEK inhibition in the metastatic setting.
Kahn A, Perry C, Etts K, Kluger H, Sznol M. Clinical predictors of longer survival in patients with BRAFV600-mutated metastatic melanoma receiving immunotherapy prior to BRAF/MEK inhibition in the metastatic setting. Journal Of Clinical Oncology 2022, 40: 9555-9555. DOI: 10.1200/jco.2022.40.16_suppl.9555.Peer-Reviewed Original ResearchBRAF/MEKiFirst-line immunotherapyBRAF/MEK inhibitionBRAF V600Metastatic melanomaLonger survivalAdverse eventsMedian durationMost patientsBone metastasesClinical predictorsDisease progressionMEK inhibitionAdvanced BRAF V600ECOG PS 0Median ECOG PSFirst-line settingKaplan-Meier methodMost common sitePredictors of survivalECOG PSMedian LDHData cutoffMetastatic settingMedian survivalFunctional Trajectories and Resilience Among Adults With Advanced Lung Cancer
Presley CJ, Arrato NA, Shields PG, Carbone DP, Wong ML, Benedict J, Reisinger SA, Han L, Gill TM, Allore H, Andersen BL, Janse S. Functional Trajectories and Resilience Among Adults With Advanced Lung Cancer. JTO Clinical And Research Reports 2022, 3: 100334. PMID: 35719868, PMCID: PMC9198463, DOI: 10.1016/j.jtocrr.2022.100334.Peer-Reviewed Original ResearchAdvanced NSCLCFunctional disabilityLung cancerBaseline Eastern Cooperative Oncology Group performance statusEastern Cooperative Oncology Group performance statusSevere disabilityPatient Health Questionnaire-9Adenocarcinoma histological subtypeDistinct functional trajectoriesAdvanced lung cancerProspective cohort studyRisk stratification toolFunctional trajectoriesLatent class trajectory modelingLung cancer treatmentWorse dyspneaBrain metastasesBaseline demographicsCohort studyFormer smokersPerformance statusBone metastasesEuroQol-5DStratification toolHistological subtypesCABOSEQ: The efficacy of cabozantinib post up-front immuno-oncology combinations in patients with advanced renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
Navani V, Wells C, Boyne D, Cheung W, Brenner D, McGregor B, Labaki C, Schmidt A, McKay R, Pal S, Meza L, Donskov F, Beuselinck B, Ernst M, Otiato M, Ludwig L, Powles T, Szabados B, Choueiri T, Heng D. CABOSEQ: The efficacy of cabozantinib post up-front immuno-oncology combinations in patients with advanced renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). Journal Of Clinical Oncology 2022, 40: 318-318. DOI: 10.1200/jco.2022.40.6_suppl.318.Peer-Reviewed Original ResearchInternational Metastatic Renal Cell Carcinoma Database ConsortiumIpilimumab-nivolumabTreatment failureOverall survivalInternational Metastatic Renal Cell Carcinoma Database Consortium criteriaInternational Metastatic Renal Cell Carcinoma Database Consortium risk groupAdvanced renal cell carcinomaResponse rateActivity of cabozantinibClinically meaningful activityRenal cell carcinomaEndothelial growth factorCell histologySarcomatoid componentBone metastasesVEGF inhibitorsPoor riskCell carcinomaCabozantinibHazard ratioRisk groupsPatientsGrowth factorTherapyEarly lines
2021
Major Salivary Gland Cancer With Distant Metastasis Upon Presentation: Patterns, Outcomes, and Imaging Implications
Benchetrit L, Mehra S, Mahajan A, Rahmati RW, Judson BL, Edwards HA. Major Salivary Gland Cancer With Distant Metastasis Upon Presentation: Patterns, Outcomes, and Imaging Implications. Otolaryngology 2021, 167: 305-315. PMID: 34784258, DOI: 10.1177/01945998211058354.Peer-Reviewed Original ResearchConceptsDistant metastasisMajor salivary gland cancerPredictors of DMRate of DMSite of DMHigh-grade mucoepidermoid carcinomaCancer-accredited hospitalsComputed tomography neckNational Cancer DatabaseCommon metastatic siteKaplan-Meier methodCox regression analysisLog-rank testSalivary duct carcinomaSalivary gland cancerRegression analysisMultivariate regression analysisHigh rateCancer presentationRetrospective cohortBone metastasesHistologic subtypeMetastatic sitesTumor histologyDuct carcinomaEvolving Patterns of Metastasis in Renal Cell Carcinoma: Do We Need to Perform Routine Bone Imaging?
Lin J, Zhang Y, Hou W, Qin Q, Galsky M, Oh W, Tsao C. Evolving Patterns of Metastasis in Renal Cell Carcinoma: Do We Need to Perform Routine Bone Imaging? Journal Of Kidney Cancer 2021, 8: 13-19. PMID: 34722126, PMCID: PMC8523177, DOI: 10.15586/jkcvhl.v8i4.202.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaRenal cell carcinomaMetastatic renal cell carcinoma patientsCell carcinomaLymph nodesBone metastasesTreatment eraIncidence of metastases to lungRate of bone metastasesIncidence of bone metastasesPhase I-III clinical trialsPattern of metastasisMetastasis to lungLymph node metastasisBone imagingTime of regulatory approvalIncidence of boneCytokine eraMetastatic diseaseMetastatic patternSecond-lineLung metastasesTreatment modalitiesMetastatic distributionKinase inhibitorsNational Quality Measure Compliance for Palliative Bone Radiation Among Patients With Metastatic Non-Small Cell Lung Cancer.
Grant S, Smith B, Colbert L, Nguyen Q, Yu J, Lin S, Chen A. National Quality Measure Compliance for Palliative Bone Radiation Among Patients With Metastatic Non-Small Cell Lung Cancer. Journal Of The National Comprehensive Cancer Network 2021, 19: 1-6. PMID: 34044365, DOI: 10.6004/jnccn.2020.7688.Peer-Reviewed Original ResearchNon-small cell lung cancerCell lung cancerMetastatic non-small cell lung cancerTreatment courseLung cancerBone metastasesSite of metastatic diseaseNational Cancer DatabaseYear of diagnosisNational Quality ForumMetastatic diseaseRadiation therapyPalliative radiationCancer DatabaseBone radiationTreatment characteristicsMultivariate analysisTreatment scheduleRate of complianceRecommended scheduleBony sitesPatientsShort courseCancerAcademic facilitiesProstate cancer intensive, non-cross reactive therapy (PRINT) for CRPC: Interim analysis of efficacy endpoints.
Liaw B, Zhong X, Tsao C, Bakst R, Stewart R, Stock R, Galsky M, Oh W. Prostate cancer intensive, non-cross reactive therapy (PRINT) for CRPC: Interim analysis of efficacy endpoints. Journal Of Clinical Oncology 2021, 39: e17027-e17027. DOI: 10.1200/jco.2021.39.15_suppl.e17027.Peer-Reviewed Original ResearchAlkaline phosphatase levelsStudy regimenPhosphatase levelsMedian time to PSA progressionCompletion of study treatmentNon-cross-resistant regimensNormalization of alkaline phosphataseTime to PSA progressionElevated alkaline phosphatase levelsProlonged disease controlPSA decline >Sequential single agentsTreatment of mCRPCNon-cross-resistant therapiesBaseline clinical featuresData cut-offDisease controlMCRPC patientsPSA progressionPSA responseGleason scoreMedian followNodal metastasisRadium-223Bone metastasesOutcomes of first-line (1L) ipilimumab and nivolumab (IPI-NIVO) and subsequent therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).
Gan C, Wells J, Schmidt A, Powles T, Tran B, Meza L, Labaki C, Lee J, Wood L, Shapiro J, Ernst D, Kapoor A, Canil C, Yuasa T, McKay R, Beuselinck B, Donskov F, Dudani S, Choueiri T, Heng D. Outcomes of first-line (1L) ipilimumab and nivolumab (IPI-NIVO) and subsequent therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). Journal Of Clinical Oncology 2021, 39: 4554-4554. DOI: 10.1200/jco.2021.39.15_suppl.4554.Peer-Reviewed Original ResearchInternational mRCC Database ConsortiumMetastatic renal cell carcinomaIpi-nivoOverall survivalCell histologyInternational mRCC Database Consortium criteriaOutcomes of first-lineTreatment durationNon-clear cell histologyPoor-risk diseaseTyrosine kinase inhibitorsRenal cell carcinomaRisk categoriesMedian OSBrain metastasesBone metastasesLiver metastasesPoor riskRisk diseaseCell carcinomaFirst-lineMedian ageProgressive diseaseMedian TDNeutrophil countThe efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) on bone oligometastatic hormone-sensitive prostate cancer: A post hoc analysis of ARCHES.
Armstrong A, Iguchi T, Azad A, Villers A, Alekseev B, Petrylak D, Szmulewitz R, Alcaraz A, Shore N, Holzbeierlein J, Gomez-Veiga F, Rosbrook B, Zohren F, Haas G, Gourgioti G, El-Chaar N, Stenzl A. The efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) on bone oligometastatic hormone-sensitive prostate cancer: A post hoc analysis of ARCHES. Journal Of Clinical Oncology 2021, 39: 5071-5071. DOI: 10.1200/jco.2021.39.15_suppl.5071.Peer-Reviewed Original ResearchMetastatic hormone-sensitive prostate cancerAndrogen deprivation therapyEfficacy of enzalutamideHormone-sensitive prostate cancerBone metastasesTreatment armsProstate cancerOligometastatic hormone-sensitive prostate cancerPrior docetaxel chemotherapySecondary clinical outcomesDeprivation therapyEfficacy outcomesRadiographic progressionSecondary endpointsBaseline characteristicsDisease volumeDocetaxel chemotherapyMetastatic burdenPolymetastatic diseaseArch studyClinical outcomesCentral reviewClinical benefitSafety profilePlaceboiRGD‐Liposomes Enhance Tumor Delivery and Therapeutic Efficacy of Antisense Oligonucleotide Drugs against Primary Prostate Cancer and Bone Metastasis
Guan J, Guo H, Tang T, Wang Y, Wei Y, Seth P, Li Y, Dehm S, Ruoslahti E, Pang H. iRGD‐Liposomes Enhance Tumor Delivery and Therapeutic Efficacy of Antisense Oligonucleotide Drugs against Primary Prostate Cancer and Bone Metastasis. Advanced Functional Materials 2021, 31 PMID: 34211360, PMCID: PMC8240484, DOI: 10.1002/adfm.202100478.Peer-Reviewed Original ResearchAndrogen receptorProstate cancerSubcutaneous xenograftsSolid tumorsAR splice variantsHigh loading efficiencySignificant side effectsProstate cancer treatmentPrimary prostate cancerBone metastasesAR expressionLoading efficiencyEfficient knockdownTumor deliverySide effectsProstate tumorsTherapeutic efficacyTumor growthTreatment studiesTumor tissueAntisense oligonucleotide drugXenograftsAntitumor efficacyCancer treatmentMetastasisA phase I/II study of combination olaparib and radium-223 in men with metastatic castration-resistant prostate cancer with bone metastases (COMRADE): A trial in progress.
Shaya J, Xie W, Saraiya B, Parikh M, Folefac E, Olson A, Choudhury A, Einstein D, Heath E, Parikh R, Kunos C, Ivy S, LoRusso P, Kurzrock R, Shapiro G, McKay R. A phase I/II study of combination olaparib and radium-223 in men with metastatic castration-resistant prostate cancer with bone metastases (COMRADE): A trial in progress. Journal Of Clinical Oncology 2021, 39: tps182-tps182. DOI: 10.1200/jco.2021.39.6_suppl.tps182.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerPhase 2 componentCastration-resistant prostate cancerPhase 1 componentBone metastasesRadium-223PARP inhibitorsPrimary endpointOverall survivalProstate cancerPhase I/II studyRadiographic progression-free survivalFirst skeletal eventKey exclusion criteriaMore bone metastasesNon-bone metastasisPhase 2 doseStratification of responsePhase 1/2 studyPrior radiation therapyPhase 1/2 trialProgression-free survivalDose-escalation designTumor immune microenvironmentPlasma cell-free DNA
2020
Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease
Collins D, Sundar R, Constantinidou A, Dolling D, Yap T, Popat S, O’Brien M, Banerji U, de Bono J, Lopez J, Tunariu N, Minchom A. Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease. BMC Cancer 2020, 20: 1210. PMID: 33298007, PMCID: PMC7724793, DOI: 10.1186/s12885-020-07662-y.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBone NeoplasmsBrain NeoplasmsClinical Trials, Phase I as TopicCombined Modality TherapyDiagnostic ImagingFemaleHumansKaplan-Meier EstimateLiver NeoplasmsLung NeoplasmsMaleMesothelioma, MalignantMiddle AgedPeritoneal NeoplasmsPleural NeoplasmsProportional Hazards ModelsRetrospective StudiesConceptsDistant metastasisPeritoneal metastasisMPM patientsTreatment paradigmCohort of MPM patientsFrequency of distant metastasesIncidence of bone metastasesPresence of distant metastasesPattern of metastatic spreadDistant metastatic diseaseDistant metastatic disseminationBackgroundMalignant pleural mesotheliomaPresence of symptomsIncidence of boneMetastatic diseaseMetastatic sitesBone metastasesOverall survivalMetastatic spreadContralateral lungPrognostic implicationsMetastatic disseminationRadiological investigationsRetrospective studyPleural mesotheliomaComparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers
Rozenblit M, Huang R, Danziger N, Hegde P, Alexander B, Ramkissoon S, Blenman K, Ross JS, Rimm DL, Pusztai L. Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers. Journal For ImmunoTherapy Of Cancer 2020, 8: e001558. PMID: 33239417, PMCID: PMC7689582, DOI: 10.1136/jitc-2020-001558.Peer-Reviewed Original ResearchConceptsPD-L1 positivity ratePD-L1 positivityPD-L1 expressionDifferent metastatic sitesPrimary tumorMetastatic sitesPositivity rateImmune cellsMetastatic lesionsTumor cellsPD-L1 protein expressionTriple-negative breast cancerMore primary tumorsTriple negative breast cancer tumorsPrimary breast lesionsPrimary outcome measureSoft tissueNegative breast cancerLow positivity rateBreast cancer tumorsBone metastasesFoundation MedicineLymph nodesPD-L1Spearman correlation coefficientCXC Chemokine/Receptor Axis Profile and Metastasis in Prostate Cancer
Nagaya N, Lee G, Horie S, Kim I. CXC Chemokine/Receptor Axis Profile and Metastasis in Prostate Cancer. Frontiers In Molecular Biosciences 2020, 7: 579874. PMID: 33195424, PMCID: PMC7593595, DOI: 10.3389/fmolb.2020.579874.Peer-Reviewed Original ResearchLymph node metastasisPrimary prostate cancerChemokines/receptorsMetastatic prostate cancerNode metastasisProstate cancerReceptor expressionMetastatic sitesChemokine/receptor axisMultivariate logistic regression analysisLog-rank test resultsLogistic regression analysisCancer Genome AtlasBone metastasesIndependent predictorsLymph nodesPostoperative recurrenceDistant metastasisCXCL10 expressionMRNA expression dataReceptor axisMetastasisTeam databaseLow expressionCancer progressionNationwide Patterns of Pathologic Fractures Among Patients Hospitalized With Bone Metastases
Jairam V, Lee V, Yu JB, Park HS. Nationwide Patterns of Pathologic Fractures Among Patients Hospitalized With Bone Metastases. American Journal Of Clinical Oncology 2020, 43: 720-726. PMID: 32694296, DOI: 10.1097/coc.0000000000000737.Peer-Reviewed Original ResearchConceptsPathologic fractureBone metastasesMultiple myelomaUtilization Project National Inpatient SampleLonger inpatient staysMultivariable logistic regressionNational Inpatient SampleIntrahepatic bile ductsRenal pelvis cancerRenal cell carcinomaProphylactic stabilizationHospital admissionPrimary cancerBile ductInpatient stayPelvis cancerCell carcinomaInpatient SamplePrimary diagnosisRisk factorsBaseline differencesOutpatient monitoringHigh riskHealthcare costsPatientsEfficacy of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) by pattern of metastatic spread: ARCHES post hoc analyses.
Shore N, Armstrong A, Szmulewitz R, Petrylak D, Holzbeierlein J, Villers A, Azad A, Alcaraz A, Alekseev B, Iguchi T, Gomez-Veiga F, Rosbrook B, Lee H, Haas G, Stenzl A. Efficacy of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) by pattern of metastatic spread: ARCHES post hoc analyses. Journal Of Clinical Oncology 2020, 38: 5547-5547. DOI: 10.1200/jco.2020.38.15_suppl.5547.Peer-Reviewed Original ResearchRadiographic progression-free survivalEfficacy of enzalutamideAndrogen deprivation therapyMetastatic hormone-sensitive prostate cancerSymptomatic skeletal eventsSoft tissue metastasesMetastatic spreadVisceral metastasesSecondary endpointsBone metastasesFirst symptomatic skeletal eventHormone-sensitive prostate cancerProstate-specific antigen progressionLarge patient subgroupPrior docetaxel treatmentProgression-free survivalSecondary endpoint measuresGreater relative efficacyNew antineoplastic therapiesM0 patientsDeprivation therapyPrimary endpointSkeletal eventsCastration resistanceDisease volume
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply